The ALBORADA Drug Discovery Institute (ADDI) at the University of Cambridge is seeking an innovative, creative, and experienced translational neuroscientist to lead and develop the institute's biology team and contribute to the vision and direction of this prestigious venture. The ADDI is a multidisciplinary group of biologists and chemists developing new therapies for neurodegenerative diseases. The biology group comprises neurobiologists, assay development and screening scientists and an in vivo biology team each supported by experienced team leaders and fully equipped laboratory space.
As Head of Biology, you will report to, and work in partnership with, the Chief Scientific Officer, Dr John Skidmore and along with the Head of Chemistry be a member of the institute's senior leadership team. You will be responsible for the scientific output and development of the biology group and will have line-management responsibility for a portfolio of projects as well as staff and budgets. Through interaction with Prof Roger Barker, the institute's Lead Academic Scientist, you will help shape our developing clinical strategy and use of human data.
Scientifically, you will take a leading role in the identification and development of new targets and projects and will be encouraged to develop new concepts and approaches. The successful applicant is expected to bring access to a wide network of potential industrial and academic partners and will be strongly encouraged to develop collaboration opportunities and new partnerships. The ADDI has core funding from Alzheimer's Research UK until Oct 2025, supplemented by significant grants from other funders. You will be encouraged and supported in raising further funding through grant applications or venture capital to develop translational projects and explore new hypotheses.
The successful applicant will have a PhD and relevant translational research expertise, with experience of an industrial research environment or an academic drug discovery unit desirable. You are expected to have an excellent understanding of mechanisms underpinning neurodegenerative disease and a good appreciation of the importance of 'omics and human data to target identification.